Bauer, M.D., Mohamed A. Hamdan, M.D., Nick Bishop, M.D., Richard E. Lutz, M.D., Mairead McGinn, M.D., Stanley Craig, M.D., Jean N. Moore, M.D., John W. Taylor, D.O., Robert H. Cleveland, M.D., William R. Cranley, M.D., Ruth Lim, M.D., Tom D. Thacher, M.D., E Jill. Mayhew, P.T., Matthew Downs, M.P.H.D., Alison M. Skrinar, M.P.H., Philippe Crine, Ph.D., and Hal Landy, M.D.: Enzyme-Substitute Therapy in Life-Threatening Hypophosphatasia.. Michael P. Whyte, M.D., Cheryl R.The price of the net-benefit result was equivalent in the two groups . The total results of the intention-to-treat, as-treated, and per-protocol analyses were in keeping with those of the principal analysis . The primary outcome within 180 days was consistent across all prespecified subgroups, including individuals who had high thrombus burden . Debate In our trial, a technique of routine manual thrombectomy during principal PCI didn’t reduce the threat of the primary outcome of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or NYHA class IV heart failure within 180 days, as compared with a technique of PCI alone with thrombectomy permitted only as bailout.